{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-226538","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2024-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.805513+00:00","generated_at":"2026-05-31T01:29:41.421731+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Catalyst earns $2.1M milestone as Japan approves FIRDAPSE for LEMS","bullets":["Japan's Ministry of Health approved DyDo's NDA for FIRDAPSE (amifampridine) 10 mg to treat Lambert-Eaton myasthenic syndrome (LEMS).","Catalyst receives JPY 300 million (~$2.1M) milestone payment from sub-licensee DyDo upon approval.","FIRDAPSE is the only FDA-approved LEMS treatment in the U.S.; approval expands access to Japan.","Catalyst CEO says approval underscores commitment to expanding rare disease product portfolio beyond the U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-226538","json":"https://secwatch.observer/filing/0001193125-24-226538.json","markdown":"https://secwatch.observer/filing/0001193125-24-226538.md","text":"https://secwatch.observer/filing/0001193125-24-226538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524226538/0001193125-24-226538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524226538/d841208d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:29:41.421731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}